Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone deacetylase IIb (HDAC IIb)
- Target
- HDAC IIb
- Molecular classification
- Enzyme, Histone modification, Transcription factor, Other (deacetylase)
01
Overview
The Histone deacetylase IIb family consists of HDAC6 and HDAC10, two zinc-dependent enzymes mainly functioning as deacetylases for both histone and non-histone proteins. HDAC6 possesses two independent catalytic domains and is localized primarily in the cytoplasm, where it participates in microtubule deacetylation, protein trafficking, and stress responses. HDAC10 contains one catalytic domain and shuttles between the nucleus and cytoplasm, with roles in DNA repair and autophagy. Both are considered promising therapeutic targets due to their involvement in cancer progression and neurodegenerative conditions. Selectivity challenges and off-target effects are important considerations in drug development for these enzymes[1][2][3][6].
- Other names
- HDAC6HDAC10Class IIb HDACs
02
Mechanism of action
Inhibition of HDAC catalytic activity; Zinc-binding group targeting (HDAC inhibitors act via zinc chelation at the active site); Regulation of acetylation status of histones and non-histone proteins
03
Biological functions
Chromatin remodelingTranscriptional repressionRegulation of gene expressionCytoskeletal organization (especially HDAC6)Cell differentiationCellular stress responseOther (non-histone protein deacetylation)
04
Disease associations
CancerNeurodegenerative diseaseInflammationOther (including possible roles in infection and cardiovascular disease)
05
Safety considerations
Off-target inhibition leading to unwanted effects due to high homology and conserved zinc-binding sitesBroad transcriptional repression impacting cell survival and differentiationPotential for neurotoxicity and cardiotoxicity, depending on inhibitor selectivityBone marrow suppression, gastrointestinal effects (common adverse events of HDAC inhibitors)
06
Interacting drugs
Vorinostat (SAHA)
5 more in the full profile.
Beyond the preview
Go deeper on Histone deacetylase IIb (HDAC IIb).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Histone deacetylase IIb (HDAC IIb).